2015
DOI: 10.1016/j.berh.2015.04.016
|View full text |Cite
|
Sign up to set email alerts
|

Pain in systemic inflammatory rheumatic diseases

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
19
0
1

Year Published

2017
2017
2022
2022

Publication Types

Select...
8
1

Relationship

2
7

Authors

Journals

citations
Cited by 32 publications
(20 citation statements)
references
References 96 publications
0
19
0
1
Order By: Relevance
“…Due to expected clinical heterogeneity between the trials, it was decided a priori to use a random-effects model for all outcomes. Heterogeneity was tested with χ 2 measured by inspection of the I2 values that describes the percentage of the variability in effect estimates that is due to heterogeneity rather than sampling error 25. An I 2 value of 0% to 40% is considered negligible, 30% to 60% represents moderate heterogeneity, 50% to 90% represents substantial heterogeneity and 75% to 100% represents considerable heterogeneity 25.…”
Section: Methodsmentioning
confidence: 99%
See 1 more Smart Citation
“…Due to expected clinical heterogeneity between the trials, it was decided a priori to use a random-effects model for all outcomes. Heterogeneity was tested with χ 2 measured by inspection of the I2 values that describes the percentage of the variability in effect estimates that is due to heterogeneity rather than sampling error 25. An I 2 value of 0% to 40% is considered negligible, 30% to 60% represents moderate heterogeneity, 50% to 90% represents substantial heterogeneity and 75% to 100% represents considerable heterogeneity 25.…”
Section: Methodsmentioning
confidence: 99%
“…The most prominent clinical feature of IRDs is pain, which may have a central as well as peripheral origin, caused by current systemic inflammation or by joint and tissue damage due to a previous inflammatory condition 2. Disease activity in IRDs is often expressed as an index of inflammation, joint damage and symptoms like pain, stiffness and fatigue.…”
Section: Introductionmentioning
confidence: 99%
“…Some of these could be related to another disorder with overlapping symptoms (34). Fibromyalgia patients generally use more antiinflammatory drugs for their chronic pain management (50). The use of modulating agents, including blocking production of pro-inflammatory cytokines and prostaglandins with anti-inflammatory drugs has been postulated to be of therapeutic value as an adjunctive therapy to the management of chronic periodontitis.…”
Section: Discussionmentioning
confidence: 99%
“…They also introduced the use of patient-reported areas of "pain or tenderness" for the WPI, whereas this assessment was restricted to physicians in the ACR 2010 criteria. These changes were suggested because it had been shown that a quarter of all FM patients failed to satisfy the 1990 ACR classification criteria [6] ; however, the new criteria did not overcome this limitation as their exclusion of inflammatory and other painful disorders means that they cannot be applied in the case of patients with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), or other similar conditions [20], [21], [22] , and do not distinguish primary and secondary FM. Furthermore, a 2010 criteria-based diagnosis requires a physician's evaluation of the extent and severity of a patient's somatic symptoms, and it is likely that the absence of the need for a physical examination will lead to possibly important physical findings and other potential causes of symptoms being overlooked [6], [7] .…”
Section: Are the 2010 Acr Criteria Better Than The 1990 Acr Criteria?mentioning
confidence: 99%